Yada Kanjanapan
YOU?
Author Swipe
View article: Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination Open
View article: Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination Open
Solid tumor malignancy (STM) patients experience increased risk of breakthrough SARS-CoV-2 infection owing to reduced COVID-19 vaccine immunogenicity. However, the underlying immunological causes of impaired neutralization remain poorly ch…
View article: Cancer metastasis to the upper gastrointestinal tract—a case series
Cancer metastasis to the upper gastrointestinal tract—a case series Open
Metastasis of non-GI primary tumours to the upper GI tract-although rare, requires clinicians to maintain a high index of suspicion when encountering unexplained GI symptoms in patients with a history of malignancy. This case series highli…
View article: Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population
Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population Open
Background Cancer patients have increased morbidity and mortality from COVID‐19, but may respond poorly to vaccination. The Evaluation of COVID‐19 Vaccination Efficacy and Rare Events in Solid Tumors (EVEREST) study, comparing seropositivi…
View article: Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant Cdk4/6 Inhibitors
Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant Cdk4/6 Inhibitors Open
View article: Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting Open
Introduction: Hyperprogressive disease (HPD) is a state of accelerated tumor growth from cancer immunotherapy, associated with poor outcome. The reported incidence is 6% to 29% among studies using varying definitions of HPD, with no predic…
View article: Management of Severe, Steroid-Resistant and Steroid-Refractory Hepatotoxicity in Patients Treated with Checkpoint Inhibitor Immunotherapy
Management of Severe, Steroid-Resistant and Steroid-Refractory Hepatotoxicity in Patients Treated with Checkpoint Inhibitor Immunotherapy Open
View article: COVID‐19 VACCINE RESPONSE IN PATIENTS ON CANCER THERAPY ‐ EVIDENCE FROM AUSTRALIAN DATA
COVID‐19 VACCINE RESPONSE IN PATIENTS ON CANCER THERAPY ‐ EVIDENCE FROM AUSTRALIAN DATA Open
systemic and microglia inflammation as described in ME/CFS.The clinical manifestation in the present case was worsening in the symptoms of the ME/CFS.The patient was already on Spironolactone targeting the increase on number of macrophages…
View article: Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy
Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy Open
Background and aims Immune checkpoint inhibitors (ICI) are increasingly used in cancer therapy. Elevated liver enzymes frequently occur in patients treated with ICI but evaluation is poorly described. We sought to better understand causes …
View article: Medical Oncology Group of Australia position statement: <scp>COVID</scp>‐19 vaccination in patients with solid tumours
Medical Oncology Group of Australia position statement: <span>COVID</span>‐19 vaccination in patients with solid tumours Open
People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID‐19). COVID‐19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS‐CoV‐2 infecti…
View article: Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy
Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy Open
The risk of infection in patients receiving immune checkpoint inhibitor (ICI) therapy is not well understood. Immune‐related adverse events requiring immunosuppressive therapy may impact infection risk. ICIs may induce an exaggerated immun…
View article: Considerations for cancer immunotherapy during the<scp>COVID</scp>‐19 pandemic
Considerations for cancer immunotherapy during the<span>COVID</span>‐19 pandemic Open
Cancer immunotherapy during the COVID-19 pandemic presents management challenges related to immune-related toxicities, requiring careful patient selection.
View article: Acute ischaemic stroke following cisplatin-based chemotherapy for testicular cancer
Acute ischaemic stroke following cisplatin-based chemotherapy for testicular cancer Open
Cisplatin is a widely used chemotherapeutic agent for many cancer types. Its toxicity profile includes drug-induced vascular damage. Clinicians should be aware of its varied presentation, including acute and chronic vascular events involvi…
View article: Impact of immunotherapy and targeted therapy on tumour growth rate in sarcoma
Impact of immunotherapy and targeted therapy on tumour growth rate in sarcoma Open
View article: Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index Open
Background Immuno-oncology (IO) is rapidly evolving in early drug development. We aimed to develop and prospectively validate a prognostic index for patients treated in IO phase I trials to assist with patient selection. Methods The develo…
View article: Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study Open
PURPOSE The ALLOCATE study was designed as a pilot to demonstrate the feasibility and clinical utility of real-time targeted molecular profiling of patients with recurrent or advanced ovarian cancer for identification of potential targeted…
View article: Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities
Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities Open
Background A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate (TGR) in comparison with pretreatment kinetics; this is known as hyperprogression. This study assessed the relation betwe…
View article: Novel patterns of response under immunotherapy
Novel patterns of response under immunotherapy Open
View article: Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology Open
Traditionally, drug development has evaluated dose, safety, activity, and comparative benefit in a sequence of phases using trial designs and endpoints specifically devised for each phase. Innovations in drug development seek to consolidat…
View article: Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination
Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination Open
View article: Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation
Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation Open
High Glut-1 in LACC is associated with poor outcome post CRT. If prospectively validated, Glut-1 may help select patients for more intensive treatment regimens.
View article: Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‐to‐lymphocyte ratio in patients with metastatic renal cell carcinoma
Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‐to‐lymphocyte ratio in patients with metastatic renal cell carcinoma Open
Background The role of cytoreductive nephrectomy ( CN ) for metastatic renal cell carcinoma ( mRCC ) in the era of targeted therapies is currently undefined. In recent years, neutrophil‐to‐lymphocyte ratio ( NLR ) has emerged as a prognost…
View article: Patterns of care for metastatic renal cell carcinoma in <scp>A</scp> ustralia
Patterns of care for metastatic renal cell carcinoma in <span>A</span> ustralia Open
Objective To examine the patterns of care and outcomes for metastatic renal cell carcinoma ( mRCC ) in A ustralia, where there are limited reimbursed treatment options. In particular, we aim to explore prescribing patterns for first‐line s…
View article: Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib Open